In contrast, numerous cell-based murine experiments have demonstrated the critical role of interactions between tumor cells and CAFs in tumor heterogeneity, with some clinical trials employing SMO inhibitors and non-specific TKIs yielding favorable outcomes. The gene discussed is SMO; the disease is neoplasm.